Core Insights - Viva Biotech is enhancing its AI-driven drug discovery capabilities by optimizing the Proteina-Complexa model to design mini-binders targeting ActRIIA, a receptor important for muscle wasting and lean mass imbalance [1][5] - The collaboration with NVIDIA emphasizes the "Lab-in-the-Loop" workflow, integrating computational design with high throughput protein production and biophysical evaluation to expedite drug discovery [2][4] - The use of AI techniques for sequence selection has led to more efficient mini-binder designs, allowing exploration of new chemical spaces and improving design specificity at reduced costs and time compared to traditional methods [3][4] Company Overview - As a leading contract research organization (CRO), Viva Biotech specializes in AI-driven drug discovery (AIDD) and structure-based drug discovery (SBDD), utilizing computational modeling, generative AI, and extensive wet lab capabilities [4] - The company aims to strengthen its AI algorithm development and enhance its drug discovery processes to deliver high-quality solutions for partners in the evolving AI-driven drug discovery landscape [4]